Aerocrine: Interim Report January - March 2013
5/7/2013 8:01:48 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Aerocrine (STO:AERO-B) secures long-term financing. US clinical sales grew by 45%.
January – March 2013
•Global Net sales decreased by 14% to SEK 33.7m (39.0)*. Adjusted for currency fluctuations, net sales decreased by 10% Year over Year (Y-o-Y).
Help employers find you! Check out all the jobs and post your resume.
comments powered by